Skip to main content
. 2014 Jul 15;5(14):5832–5844. doi: 10.18632/oncotarget.2200

Figure 2. HERG1 siRNA silencing inhibits pancreatic cancer progression in vitro and vivo.

Figure 2

(A) HERG1 gene expression silencing reduced HERG1 mRNA (a) and protein (b) expression in PANC-1 and CFPAC-1 cells; (B) PANC-1 and CFPAC-1 growth curve after HERG1 siRNA, NC siRNA transfection or without treatment (MTT assay). The growth index was assessed at 1, 2, 3, 4, and 5 d; (C) Flow cytometery analysis of apoptosis in PANC-1 and CFPAC-1 cells after HERG1 siRNA, NC siRNA transfection or without treatement; (D) Flow cytometery analysis of cell cycle progression in PANC-1 and CFPAC-1 cells after HERG1 siRNA, NC siRNA transfection or without treatement; (E) Migration and invasion assay analysis of PANC-1 and CFPAC-1 cells after HERG1 siRNA, NC siRNA transfection or no treatement. (F) The growth curve (a) and weight of tumors (b) derived from the untreated, NC siRNA-transfected, and HERG1 siRNA-transfected CFPAC-1 cells injected into the left flank of 4-week-old female BALB/c nu/nu mice. (G) Metastatic nodules (a) and haematoxylin and eosin staining (H&E) (b) derived from the untreated, NC siRNA-transfected, and HERG1 siRNA-transfected CFPAC-1 cells injected into the pancreatic capsule of 4-week-old female BALB/c nu/nu mice. Magnification for H&E is ×40. All data are shown as mean ± SD. * P < 0.05; ** P < 0.01.